Restaurant critic Giles Coren reveals he has prostate cancer
The former BBC presenter, 55, said he was diagnosed on Wednesday with a malign tumour.
Mr Coren wrote in The Times that he was first tested for the cancer after Sir Stephen Fry and Bill Turnbull, the late television and radio presenter, announced they had the disease.
When he first took a PSA test, which measures the amount of prostate specific antigen (PSA) in a person's blood, he received a score of four – anything more than three is deemed abnormal for a man.
However, he refused a biopsy after an MRI scan result was inconclusive.
It was only after his PSA score increased to six and then seven that he agreed to have a biopsy at the Royal Free Hospital in London.
Mr Coren, who has appeared in BBC shows including Supersize Me, Our Food, and Amazing Hotels, said doctors found less than 1mm of cancer in three of the 21 samples taken.
His 'malign tumour' did not require treatment at present but would be monitored for growth, he added.
Mr Coren wrote: 'How about this for a piece of couldn't-make-it-up professional timing: in the very week that it was announced on the front page of The Times that prostate cancer is now the commonest cancer in England … I have been diagnosed with it!'
NHS data revealed this week that prostate cancer was now the most common in England after a 25 per cent rise in cases over the past five years.
A record 55,000 men were diagnosed with it in 2023, up from 44,000 in 2019, according to Prostate Cancer UK analysis.
Men over the age of 50 – or 45 if they are black – can ask their GP for a PSA test but GPs are not allowed to offer them to anyone without symptoms, leading to thousands of late diagnoses.
Sir Chris Hoy revealed in October that he has 'two to four years' left to live after being diagnosed with terminal prostate cancer.
Earlier this month, a breakthrough in prostate cancer treatment saw a drug shrink tumours in advanced disease.
The experimental medicine, also being trialled for ovarian disease, could help men who are no longer responding to treatment.
Experts hailed the discovery as an 'exciting step' towards tackling treatment resistance for patients with the disease.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Hidden health benefits from weight-loss shots revealed
Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious conditions such as dementia and stroke, a new study has indicated. The research also suggests that individuals with type 2 diabetes and obesity who are prescribed these medications could face a reduced risk of premature death. Academics behind the study noted that while the efficacy of GLP agonist drugs – such as semaglutide (found in Wegovy and Ozempic) and tirzepatide (Mounjaro) – in managing weight and blood sugar levels is widely recognised, their wider health benefits have remained less understood. The comprehensive study, conducted by experts in Taiwan, examined data from 60,000 people worldwide, with an average age of 58, all diagnosed with type 2 diabetes and obesity. Roughly half of the participants were given GLP agonist drugs. These medications function by curbing appetite, slowing digestion, reducing the liver's sugar output, and enhancing the body's insulin production when required. The other half used other anti-diabetic medication. During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37 per cent lower risk of dementia and a 19 per cent reduced risk of stroke. Weight-loss drugs like Wegovy are available on the NHS to obese patients They were also 30 per cent less likely to die during the follow-up period. When researchers looked at the data further, they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Yahoo
2 hours ago
- Yahoo
Dermot Murnaghan 'fell through the cracks' with prostate cancer diagnosis
Former Sky News presenter Dermot Murnaghan has said he "fell through the gaps" with his prostate cancer diagnosis, calling it a "massive wake-up call". He revealed last month , meaning it has spread to other areas of the body. However, he said he was responding positively to treatment. Speaking at an event for Prostate Cancer UK, Murnaghan urged men to get tested - and to insist on one if they're in a high-risk group. "For years I thought 'that will do me'. I'm getting tested basically once a year or every couple of years," he said. "It never occurred to me that they weren't testing for PSA (prostate-specific antigen) and I never went to my GP because I was getting other tests privately through the production company. "So that's how I fell through the gaps and that's how I had a massive wake-up call and want to share the message." A PSA test is a blood test that can indicate if there's a potential problem with the prostate but there's currently no national screening programme. The NHS says men over 50 can ask their GP for one, and Murnaghan, who's 67, said some people below that age should also push for one. "You can get to the stage I have with no symptoms," he said. "Get the test, insist on the test. You can insist on the test if you are in a high-risk group and under 50. If you are not, I'd still get the test at 50." Read more from Sky News: Murnaghan - who worked at Sky News for 16 years - added: "Go to your GP and they say you don't need it, but say 'but I want it'. It is your right to have it. "Just keep doing that every year or couple of years. Once you've got that marker where your PSA is, keep monitoring it. "The earlier you find prostate the easier it is to treat, so check your risk in just 30 seconds with Prostate Cancer UK's to see if you are at risk and what you can choose to do about it." Those at higher-risk of prostate cancer include men over 50, black men and people with a family history of the disease. Murnaghan is currently preparing for a charity bike ride in September, the Tour de 4, organised by Sir Chris Hoy - who revealed last year.
Yahoo
3 hours ago
- Yahoo
Why the UK is lagging behind other countries on measles vaccinations
The UK is the worst-performing G7 country for coverage of measles vaccines, as rates lag behind Europe, with experts warning declining health budgets and the spread of misinformation are putting children at risk. Now, health officials in the UK have sounded the alarm over our waning vaccine coverage after a child with measles died in Liverpool. On Monday, health secretary Wes Streeting said that the child's death shows the nation needs to 'redouble its efforts' to vaccinate more children and said improvements promised in the NHS's 10-year plan, such as giving parents access to digital health records, could help. One expert told The Independent a multitude of issues have impacted the UK's measles vaccination rates, including declining public health budgets, lower access to GP services, and the increased circulation of misinformation on social media. Data published by the World Health Organisation (WHO) and the charity UNICEF estimates the UK has just 89 per cent coverage of the first measles vaccine in 2024 and 85 per cent coverage of the second dose. This is down from 93 per cent a decade earlier and well below WHO target of 95 per cent, which it said is needed to effectively eliminate the spread of the disease in the community. And we're lagging well behind our G& counterparts, with vaccine rates in Germany the highest (96 per cent), Italy and France (95 per cent) and Japan (94 per cent)/. The organisations warned that the global rates of childhood vaccinations are falling, with 30 million children unvaccinated. Rates of the first MMR vaccine across the UK have been in decline since 2014. An analysis by the Nuffield Trust of 2023-24 data shows England lags behind Wales, Scotland and Northern Ireland on coverage of this vaccine. Within England, London has the worst coverage by far, with just 81 per cent of children having received a first course by their second birthday. Data as of June 2025 shows that the capital accounted for 44 per cent of all measles cases. Measles is a highly contagious, serious airborne disease caused by a virus that can lead to severe complications and death. Dr Connor Bamford, Virologist, Queen's University Belfast, explained: 'Various conditions can make individuals more vulnerable to severe measles. This may include immunosuppressed individuals undergoing cancer treatment for example who, because of their condition, have lost immunity to the virus, even if they have been vaccinated." He said: "We do see children and adults dying from measles in the UK and the last young person who died was reported in 2024. In 2023, we saw another child die of a disease called SSPE (subacute sclerosing panencephalitis), which is a fatal complication of measles that occurs years after an earlier infection. In 2023 two adults also died." In the UK, immunisation against it is typically given as part of the MMR vaccine for measles, mumps and rubella. According to the NHS, around 99 per cent of people who receive the MMR vaccine will be protected against measles and rubella. Meanwhile, around 88 per cent will be protected against mumps, and anyone who does get it after vaccination will experience milder symptoms. According to the Nuffield Trust, uptake of the MMR vaccine decreased significantly following a now discredited article by Dr Andrew Wakefield in 1998, which linked MMR vaccination to autism. By 2003-04 uptake of the vaccine had dropped to 80 per cent. However, coverage then improved and hit 93 per cent in 2013-14, before dropping again to 89 per cent in 2023-24. A recent survey by the UK Health Security Agency (UKHSA) suggested that overall, parents in the UK have a high level of confidence that vaccines work for children, with 87 per cent of those surveyed having agreed with this. However, vaccine coverage for MMR and other key childhood vaccines has declined in recent years, and now health officials are urging parents to get their children vaccinated. Speaking with The Independent, Adam Finn, Professor of Paediatrics at the University of Bristol, and a member of the government's Joint Vaccinations and Immunisations Committee, explained there were several factors, including the fact that there has been a general decline in immunisation over the past 15 years, which had initially been ignored. He said: 'The public health authority officials favour the idea that it's because there's been a waning of resource in the health service to deliver the vaccine programme, so as primary care in particular has become more stretched the capacity to chase people up and go after the people that are otherwise not getting their act together has disappeared and that's resulted in the vulnerable edge getting worse and worse.' 'The competing hypothesis, which is quite convenient for the politicians, is that it's mad internet misinformation, and in a sense, people are somehow to blame for believing it and that it's not really a governmental problem, it's myth and legend, as it were.' 'My view is that those two things are not mutually exclusive.' He said while there are a group of parents and people who avoid vaccination, there are another group who don't do it because they're not aware, or it's not high up on their priority list. The professor of paediatrics also suggested that vaccines, such as MMR, were a victim of their own success, with the public no longer having a living memory of the severe and life-threatening impacts of the disease. In the 1960s, people would've queued around the block to get their children immunised because they were afraid of them dying of those diseases where whereas now they've never heard of them, he said. One key solution is enabling healthcare workers, such as GPs or health visitors, to have conversations around vaccines with parents, says Professor Finn. 'The government has come in with a mission to solve the problem of the under-resourced health service and has emphasised the way it wants to do that is to stop people from getting ill rather than build more hospitals. 'And one of the most obvious and effective, proven and countable ways of doing that is to ensure vaccine programmes are delivered, and so I think it should be a fairly open and closed argument that this is where Wes Streeting needs to put his money.' Where access to GPs and health visitors is an issue, experts have suggested expanding the list of places where parents can get vaccines, and information about them could help. Malcolm Harrison, Chief Executive of the Company Chemists' Association (CCA), has suggested pharmacies could assist. He said last year, a pilot in the North West of England allowed children aged 5 to 11 who had missed doses to get the MMR vaccine at their local pharmacy for the first time. Experts have also suggested that schools could be an important place for children's vaccines to be accessed.
